

VIDAL Group acquires GPR, providing prescription support tool for renal failure in France

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: <https://corporate.m3.com/en/>; “M3” below) has announced the acquisition via M3’s European subsidiary VIDAL Group (“Vidal” below), of GPR (officially registered as GPR SAS; Headquarters: Paris, France; “GPR” below), which provides a drug database and prescription supporting tool for patients with renal failure both in France and internationally.

In France, M3 acquired Vidal in 2016, which provides prescription management software solutions. The drug database managed by Vidal is used by approximately 200,000 physicians in France. In addition, Vidal is a market leader in the field of cloud-based practice management software and offers several solutions such as Weda and DrSanté to more than 40,000 healthcare professionals, including approximately 20,000 physicians.

Since its establishment in 2010, GPR has provided a database based on scientific literature that indexes about 4,000 drugs and compounds in relation with renal failure, and has developed and sold drug dosage calculation tools for patients with renal failure. Since the renal function plays an important role in the assimilation of drugs, careful adjustments are required when prescribing drugs to patients with renal failure. With the use of GPR, physicians can calculate appropriate dosages based on each patient’s parameters. GPR is a key source of information on renal failure treatment for many physicians both in France and internationally, and the number of its users has reached 40,000 among physicians in 2024.

Since GPR and Vidal signed a distribution agreement in 2023, GPR has been accessible directly through “Vidal Hoptimal,” Vidal’s hospital prescription support system. Following the acquisition, GPR will be further integrated into Vidal’s clinical prescription support tools in order to mutually reinforce the products. By leveraging Vidal’s overwhelming physician membership base and brand recognition in France, GPR will be able to deliver its services to even more healthcare professionals.

It is estimated that approximately 15% of adults worldwide have some form of kidney dysfunction¹, and this number is expected to grow further in the future due to an aging population and the associated increase in chronic diseases. M3 Group continues to contribute to addressing medical challenges as a leading provider of solutions for the medical field, including the collaboration with GPR in respect of patients suffering from renal failure, while aiming for further growth.

¹ Based on estimates from the International Society of Nephrology and the UN World Population Prospects 2024

■ Overview of GPR

[Company name] SAS GPR

[Established] 2010

[Headquarters] Paris, France

[URL] <https://www.vidal.fr/gpr/articles.html>

[Business] Development and sale of database of literature and drugs, and prescription support tools, all related to patients with renal failure

■ Screenshot of GPR, diagnostic supporting tool for renal failure

(example: calculation supporting tool of patient's renal function)

ViDAL Médicaments DM & Parapharmacie Maladies Santé des patients Prise en charge médicale Formations médicales Qui sommes-nous ? Vincent Hillenmeyer >

Rein - Estimation de la fonction rénale

Articles Adaptation de posologie Toxicité rénale Estimation de la fonction rénale Ressources scientifiques

Âge *

Créatininémie *

☐ µmol/l ☐ mg/l ☐ mg/dl

Sexe *

☐ Homme ☐ Femme

Poids (kg)

Taille (cm)

Origine ethnique *

☐ Afro-Américain ☐ Non Afro-Américain

* champs obligatoires

Calculer